Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 84-88

  Zarogoulidis, K ^a   Eleftheriadou, E ^a   Kontakiotis, Th ^a   Gerasimou, G ^a   Zarogoulidis, P ^a   Sapardanis, I ^a   Galaktidou, G ^b   Sakkas, L ^c   Gotzamani Psarrakou, A ^a   Karatzas, N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Thiagenio Anticancer Institute Research Laboratory   (Greece)

^c 'G Papanikolaou' Hospital   (Greece)

Author keywords

Antiproliferative effect; HER2; IGF1; Long acting somatostatin analogues; NSE; Small cell lung cancer; VEGFA; VEGFC; VEGFR2

Indexed keywords

ANGIOPEPTIN; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PACLITAXEL; PROTEIN BCL 2; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARBOPLATIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OCTREOTIDE; PACLITAXEL; PEPTIDES, CYCLIC; PROGNOSIS; RECEPTORS, SOMATOSTATIN; SMALL CELL LUNG CARCINOMA; SOMATOSTATIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84858006528     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.014     Document Type: Article

References (25)

1. Newman J.B., Lluis F., Townsend C.M. Somatostatin. Gastrointestinal endocrinology 1987, 286-299. McGraw-Hill Book Co, New York. J.C. Thompson, G.H. Greeley, P.L. Rayford, C.M. Townsend (Eds.).
2. Volante M., Rosas R., Allia E., Granata R., Baragli A., Muccioli G. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 2008, 286:219-229.
3. Taboada G.F, Luque R.M., Bastos W., Guimarães R.F., Marcondes J.B., Chimelli L.M., et al. Quantitative analysis of somatostatin receptor subtype (SST1-5) gene express levels in somatostropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007, 156:56-74.
4. O'Byrne K.J., Schally A.V., Thomas A., Carney D.N., Steward W.P. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy 2001, 47(Suppl. 2):78-108. [Review].
5. Pyronnet S., Bousquet C., Najib S., Azar R., Laklai H., Susini C. Antitumour effects of somatostatin. Mol Cell Endocrinol 2008, 286:230-237.
6. Grimberg A. Somatostatin and cancer: applying endocrinology to oncology. Cancer Biol Ther 2004, 3:731-733.
7. Arvigo M., Gatto F., Ruscica M., Ameri P., Dozio E., Albertelli M., et al. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J Endocrinol 2010, 207(December (3)):309-317. [Epub 2010 September 27].
8. Weckbecker G., Rauld F., Stolz B., Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993, 60:245-264.
9. Weckbecker G., Lewis I., Albert R., Schmid H.A., Hoyer D., Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003, 2:999-1017.
10. Berenger N., Moretti J.L., Boaziz C., Vigneron N., Morere J.F., Breau J.L. Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer 1996, 32:1429-1431.
11. Smith M.C., Liu J., Chen T., Schran H., Yeh C.M., Jamar F., et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplatis therapy. Digestion 2000, 62:69-72.
12. Prévost G., Bourgeois Y., Mormont C., Lerrant Y., Veber N., Poupon M.F., et al. Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6. Life Sci 1994, 55(2):155-162.
13. Reubi J.C., Kvols L.K., Waser B., Nagorney D.M., Heitz P.U., Charboneau J.W., et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990, 50:5969-5977.
14. Reubi J.C., Schae J.C., Markwalder R., Waser B., Horisberger U., Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 1997, 70:471-479.
15. Talbot-Smith A., Fritschi L., Divitini M.L., Mallon D.F., Knuiman M.W. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003, 157(7):606-612.
16. Mentlein R., Eichler O., Forstreuter F., Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 2001, 92:545-550.
17. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
18. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007, 13:1961-1970.
19. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2059.
20. Sun LC, Coy DH., Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv. 2011 Jan;8(1):2-10. Review.
21. Yan J.J., Chen F.F., Tsai Y.C., Jin Y.T. Immunohistochemical detection of bcl-2 protein in small cell carcinomas. Oncology 1996, 53:6-11.
22. Jiang S.X., Sato Y., Kumao S., Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995, 177:135-138.
23. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
24. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
25. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.